Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation

DINARELLO, C

doi:10.1016/j.coph.2004.03.010

Cited by 195Inflammasome and immune disordersRheumatoid Arthritis Research and TherapiesCytokine Signaling Pathways and Interactions

Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation

DINARELLO, C·2004·Current Opinion in Pharmacology

DOI 10.1016/j.coph.2004.03.010

Open this paper in CoChat — free account

Abstract

All biological agents currently used for reducing TNFalpha activity in disease are neutralization strategies; however, there are several strategies for reducing interleukin (IL)-1 activities: the IL-1 receptor antagonist (IL-1Ra), anti-IL-1beta monoclonal antibodies, the IL-1 Trap, IL-1 receptor type I antibodies, antibodies to the IL-1 receptor accessory chain and inhibitors of IL-1beta-converting enzyme, now termed caspase-1. In fact, caspase-1 inhibitors are the first orally active agents that target cytokines, as these inhibitors prevent the processing and release of active forms for IL-1beta and IL-18, which is a member of the IL-1 family. The IL-1 Trap is a new concept in using soluble forms of cytokine receptors to bind and neutralize a specific cytokine. The Trap takes advantage of the high affinity of the two signaling chains of the cell surface IL-1 receptor linked by the Fc portion of IgG1. The IL-1Ra is currently approved to treat rheumatoid arthritis; in over 75 000 patients, the IL-1Ra has provided insights into the role of IL-1 in local and systemic inflammation, as well as the safety of long-term reduction of IL-1 activity.

Integrity signals

Registry

Crossref · 10.1016/j.coph.2004.03.010

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The NLRP-3 inflammasome plays a role in the pathophysiology of many inflammatory diseases, including obesity, insulin resistance, and diabetes.
“The NLRP-3 inflammasome plays a role in the pathophysiology of many inflammatory diseases, including obesity, insulin resistance, and diabetes (21,31–35).”
From Sustained Inflammasome Activity in Macrophages Impairs Wound Healing in Type 2 Diabetic Humans and Mice (2014) · cites this paper as [31]
Clinical successes using drugs that specifically inhibit TNF in inflammatory bowel disease or rheumatoid arthritis directly implicate a pathogenic role of TNF in other diseases and validate the cytokine theory of disease in humans.
“Clinical successes in the 1990s using drugs that specifically inhibit TNF for patients with inflammatory bowel disease or rheumatoid arthritis directly implicated a pathogenic role of this cytokine in other diseases (7-9) and validated in humans the fundamental premise of the cytokine theory of disease.”
From Physiology and immunology of the cholinergic antiinflammatory pathway (2007) · cites this paper as [8]

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S. K., Wise, R. P., Mirabile‐Levens, E., Kasznica, J. M., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,683 · see citing works
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 3,380 · see citing works
Self-citation
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · see citing works
Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,679 · see citing works
Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in mice
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,678 · see citing works
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., & O'Connor, J. V. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.6.1433 · Cited by 1,472 · see citing works
Self-citation
INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS
Brennan, F. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,133 · see citing works
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.
Auron, P. E., Webb, A. C., Rosenwasser, L. J., Mucci, S. F., Rich, A., Wolff, S. M., & Dinarello, C. A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7907 · Cited by 1,042 · see citing works
Self-citation
Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v75.1.40.40 · Cited by 1,012 · see citing works
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y. K., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977 · see citing works
Altered Cytokine Production in Mice Lacking P2X7Receptors
Solle, M., Labasi, J. M., Perregaux, D. G., Stam, E. J., Petrushova, N., Koller, B. H., Griffiths, R., & Gabel, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006781200 · Cited by 924 · see citing works
Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 743 · see citing works
NALPs: a novel protein family involved in inflammation
Tschopp, J., Martinon, F., & Burns, K. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1019 · Cited by 719 · see citing works
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N. L., Rosenberg, A. S., Song, X., Shealy, D. J., & Wagner, C. L. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 671 · see citing works
Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.
Fong, Y., Tracey, K. J., Moldawer, L. L., HESSE, D. G., Manogue, K., Kenney, J. S., Lee, A. T., Kuo, G. C., ALLISON, A. C., & Lowry, S. F. (1989) · The Journal of Experimental Medicine · doi:10.1084/jem.170.5.1627 · Cited by 640 · see citing works
Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor.
Tartaglia, L. A., Pennica, D., & Goeddel, D. V. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46661-0 · Cited by 570 · see citing works
Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology
Mohan, V. P., Scanga, C. A., Yu, K., Scott, H. M., Tanaka, K. E., Tsang, E., Tsai, M. C., Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1847-1855.2001 · Cited by 532 · see citing works
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531 · see citing works
CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS
Eastgate, J. A., Wood, N. C., di Giovine, F. S., Symons, J. A., Grinlinton, F. M., & Duff, G. W. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90185-7 · Cited by 484 · see citing works
The Secretory Route of the Leaderless Protein Interleukin 1β Involves Exocytosis of Endolysosome-related Vesicles
Andrei, C., Dazzi, C., Lotti, L. V., Torrisi, M. R., Chimini, G., & Rubartelli, A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.5.1463 · Cited by 475 · see citing works
Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial
Fleischmann, R., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G. R., Tesser, J., Modafferi, D., Poulakos, J. J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392 · see citing works
Multiple biological activities of human recombinant interleukin 1.
Dinarello, C. A., Cannon, J. G., Mier, J. W., Bernheim, H. A., LoPreste, G., Lynn, D., Love, R. N., Webb, A. C., Auron, P. E., & Reuben, R. C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112495 · Cited by 366 · see citing works
Self-citation
Cytokine traps: multi-component, high-affinity blockers of cytokine action
Economides, A. N., Carpenter, L. R., Rudge, J. S., Wong, V., Koehler-Stec, E. M., Hartnett, C., Pyles, E. A., Xu, X., Daly, T. J., Young, M. R., et al. (2002) · Nature Medicine · doi:10.1038/nm811 · Cited by 360 · see citing works
The bath ankylosing spondylitis radiology index (BASRI): A new, validated approach to disease assessment
Mackay, K., Mack, C., Brophy, S. T., & Călin, A. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12 · Cited by 327 · see citing works
Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever
Hoffman, H. M., Wanderer, A. A., & Broide, D. H. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118790 · Cited by 325 · see citing works
Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae
Ottenhoff, T. H. M., Verreck, F. A. W., Lichtenauer-Kaligis, E. G. R., Hoeve, M. A., Sanal, Ö., & van Dissel, J. T. (2002) · Nature Genetics · doi:10.1038/ng0902-97 · Cited by 244 · see citing works
Binding of IL-1 alpha , IL-1 beta , and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids.
Arend, W. P., Malyak, M., Smith, M. F., Whisenand, T. D., Slack, J. L., Sims, J. E., Giri, J. G., & Dower, S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.10.4766 · Cited by 241 · see citing works
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
Wallis, R. S., Kyambadde, P., Johnson, J. L., Horter, L., Kittle, R., Pohle, M., Ducar, C., Millard, M., Mayanja‐Kizza, H., Whalen, C. C., et al. (2004) · AIDS · doi:10.1097/00002030-200401230-00015 · Cited by 224 · see citing works
Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli
Wherry, J., Schreiber, R. D., & Unanue, E. R. (1991) · Infection and Immunity · doi:10.1128/iai.59.5.1709-1715.1991 · Cited by 210 · see citing works
Protective Role of Interleukin-1 in Mycobacterial Infection in IL-1 α/β Double-Knockout Mice
Yamada, H., Mizumo, S., Horai, R., Iwakura, Y., & Sugawara, I. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780079 · Cited by 209 · see citing works
Interleukin-18 Regulation of Interferon γ Production and Cell Proliferation as Shown in Interleukin-1β–Converting Enzyme (Caspase-1)-Deficient Mice
Fantuzzi, G., Puren, A. J., Harding, M. W., Livingston, D. J., & Dinarello, C. A. (1998) · Blood · doi:10.1182/blood.v91.6.2118 · Cited by 196 · see citing works
Self-citation
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.
Smith, J. W., Urba, W. J., Curti, B. D., Elwood, L. J., Steis, R. G., Janik, J. E., Sharfman, W. H., Miller, L. L., Fenton, R. G., & Conlon, K. C. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1141 · Cited by 162 · see citing works
The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic mice
Probert, L., Plows, D., Kontogeorgos, G., et al. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250647 · Cited by 157 · see citing works
Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
Gottlieb, A. B., Masuda, S., Ramamurthi, R., et al. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.10 · Cited by 157 · see citing works
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer
Crown, J. P., Jakubowski, A. A., Kemeny, N. E., Gordon, M. S., Gasparetto, C., Wong, G. G., Sheridan, C., Toner, G. C., Meisenberg, B., & Botet, J. F. (1991) · Blood · doi:10.1182/blood.v78.6.1420.1420 · Cited by 142 · see citing works
The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin
Smith, J. W., Longo, D. L., Alvord, W. G., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303183281103 · Cited by 139 · see citing works
Identification of a Locus on Chromosome 1q44 for Familial Cold Urticaria
Hoffman, H. M., Wright, F. A., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2000) · The American Journal of Human Genetics · doi:10.1086/302874 · Cited by 137 · see citing works
Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept
Zou, J., Rudwaleit, M., Brandt, J., Thiel, A., Braun, J., & Sieper, J. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.6.561 · Cited by 129 · see citing works
Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment
Ulfgren, A. ‐., Gröndal, L., Lindblad, S., et al. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.6.439 · Cited by 121 · see citing works
Down‐regulation of the nonspecific and antigen‐specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab
Zou, J., Rudwaleit, M., Brandt, J., Thiel, A., Braun, J., & Sieper, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10847 · Cited by 103 · see citing works
Successful treatment of refractory adult-onset Still?s disease with infliximab. A prospective, non-comparative series of four patients
Kokkinos, A. D., Iliopoulos, A., Greka, P., et al. (2004) · Clinical Rheumatology · doi:10.1007/s10067-003-0775-5 · Cited by 96 · see citing works
Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P
Hoffman, H. M., Gregory, S. G., Mueller, J. L., et al. (2003) · Human Genetics · doi:10.1007/s00439-002-0860-x · Cited by 88 · see citing works
Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans
Granowitz, E. V., Porat, R., Mier, J. W., Orencole, S. F., Callahan, M., Cannon, J., Lynch, E., Ye, K., Poutsiaka, D., & Vannier, E. G. (1993) · Blood · doi:10.1182/blood.v82.10.2985.2985 · Cited by 86 · see citing works
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade
Buch, M. H., Bingham, S. J., Seto, Y., McGonagle, D., Bejarano, V., White, J., & Emery, P. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20115 · Cited by 75 · see citing works
Interleukin-1: Biological Effects in Human Hematopoiesis
Crown, J., Jakubowski, A. A., & Gabrilove, J. L. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309145750 · Cited by 38 · see citing works
Tumor Necrosis Factor (TNF)–α–Induced Interleukin‐8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble Receptors
Frishman, J. I., Edwards, C. K., Sonnenberg, M. G., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/317605 · Cited by 36 · see citing works
Untitled work
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11

Flagged first, then by citations

Sorted by citations

Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · see citing works
Self-citation
Physiology and immunology of the cholinergic antiinflammatory pathway
Tracey, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30555 · Cited by 1,563 · see citing works
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170 · see citing works
Sustained Inflammasome Activity in Macrophages Impairs Wound Healing in Type 2 Diabetic Humans and Mice
Mirza, R. E., Fang, M. M., Weinheimer-Haus, E. M., Ennis, W. J., & Koh, T. J. (2014) · Diabetes · doi:10.2337/db13-0927 · Cited by 319 · see citing works
“The NLRP-3 inflammasome plays a role in the pathophysiology of many inflammatory diseases, including obesity, insulin resistance and diabetes (21; 31-35).”
Background
Therapeutic Neutralization of the NLRP1 Inflammasome Reduces the Innate Immune Response and Improves Histopathology after Traumatic Brain Injury
de Rivero Vaccari, J. P., Lotocki, G., Alonso, O. F., Bramlett, H. M., Dietrich, W. D., & Keane, R. W. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.46 · Cited by 312 · see citing works
Interleukin-1β–Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen–Induced Tumors
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285 · see citing works
Self-citation
Interleukin-1, inflammasomes, autoinflammation and the skin
Contassot, E., Beer, H.-D., & French, L. E. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13590 · Cited by 130 · see citing works
Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity
Zhang, C., Feng, J., Du, J., Zhuo, Z., Yang, S., Zhang, W., Wang, W., Zhang, S., Iwakura, Y., Meng, G., et al. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.22 · Cited by 99 · see citing works
Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection
Muehlenbachs, A., Fried, M., Lachowitzer, J., Mutabingwa, T. K., & Duffy, P. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.557 · Cited by 81 · see citing works
Imbalance in the peritoneal levels of interleukin 1 and its decoy inhibitory receptor type II in endometriosis women with infertility and pelvic pain
Akoum, A., Al-Akoum, M., Lemay, A., Maheux, R., & Leboeuf, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.06.019 · Cited by 78 · see citing works
Depression and Anxiety in Multiple Sclerosis Patients: The Role of Genetic Variability of Interleukin 1β
Ferreira, A. M., Leal, B., Ferreira, I., Brás, S., Moreira, I., Samões, R., Sousa, A. P., Santos, E., Silva, B., Costa, P. P., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102982 · Cited by 17 · see citing works

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Meyer, N. J., Reilly, J. P., Anderson, B. J., Palakshappa, J. A., Jones, T. K., Dunn, T. G., Shashaty, M. G. S., Feng, R., Christie, J. D., & Opal, S. M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002749 · Cited by 99 · see citing works
Studying the Pharmacokinetics of Interleukin-1RA Mutants
Khuzaima, I., Iftikhar, K., Tabarruk, U., et al. (2019) · BioScientific Review · doi:10.32350/bsr.0101.02 · Cited by 1 · see citing works
Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats
Schwab, J. H., Anderle, S. K., Brown, R. R., Dalldorf, F. G., & Thompson, R. C. (1991) · Infection and Immunity · doi:10.1128/iai.59.12.4436-4442.1991 · Cited by 154 · see citing works
The natural interleukin-1 receptor antagonist prevents interleukin-l-induced preterm delivery in mice
Romero, R. J., & Tartakovsky, B. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(12)80035-4 · Cited by 215 · see citing works
The role of interleukin-1β in febrile seizures
Heida, J. G., Moshé, S. L., & Pittman, Q. J. (2009) · Brain and Development · doi:10.1016/j.braindev.2008.11.013 · Cited by 111 · see citing works

Authors: DINARELLO, C.
Affiliations: University of Colorado Health (US)
Corresponding author: DINARELLO, C
ORCID: DINARELLO, C
Venue: Current Opinion in Pharmacology
Publisher: Elsevier BV
Published: 2004-08
Volume: 4
Issue: 4
Pages: 378-385
ISSN: 1471-4892 (ISSN-L)
DOI: 10.1016/j.coph.2004.03.010
OpenAlex: W1967436988
Cited by: 195
References: 47
Citations by year: 2026: 5 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 10 · 2015: 2 · 2014: 4 · 2013: 7 · 2012: 11
FWCI: 6.75
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Opinion in Pharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Amgen
National Institutes of Health
National Heart, Lung, and Blood Institute (HL68743, P01HL068743)
National Institute of Allergy and Infectious Diseases (AI‑15614)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Keywords: interleukin-1, interleukin-1 receptor antagonist, anti-IL-1β monoclonal antibody, caspase-1 inhibitors, IL-1β, IL-18, rheumatoid arthritis, cytokine neutralization
MeSH terms: Animals, Humans, Inflammation, Interleukin-1, Tumor Necrosis Factor-alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks